June 11, 2026 1:52 am

Tag: ulcerative colitis

$420M Partnership Brings New Hope for Better IBD Treatments

A new $420 million partnership between Genentech and OMass Therapeutics is developing innovative oral IBD treatments using groundbreaking protein research technology. This collaboration represents significant hope for better treatment options that could transform daily life for millions living with Crohn’s disease and ulcerative colitis.

New Hope on the Horizon: TREMFYA® Gets NICE Approval for IBD

NICE has officially recommended TREMFYA® as a treatment for both Crohn’s disease and ulcerative colitis, offering new hope for patients who haven’t found success with previous therapies. This breakthrough represents a meaningful step forward for the IBD community, with evidence showing effectiveness across different patient populations.

You Missed

Probiotics and IBD: What 20+ Years of Living with Crohn's Taught Me

Probiotics and IBD: What 20+ Years of Living with Crohn’s Taught Me

May 26, 2026
Week of May 18-24, 2026: 4 IBD research stories worth your attention

Week of May 18-24, 2026: 4 IBD research stories worth your attention

May 26, 2026
Week of May 11-17, 2026: Seven IBD research stories worth your attention

Week of May 11-17, 2026: Seven IBD research stories worth your attention

May 17, 2026